Clinical trials: Chronic Liver Disease, open to volunteers
Steatohepatitis, Nonalcoholic, Steatosis of Liver
Ketogenic Diet in MASLD-related cACLD
The investigators hypothesize that very low ketogenic diet could represent a new therapeutic option in the management of patients with MASLD and cACLD.
- Conditions
- Steatohepatitis, Nonalcoholic, Steatosis of Liver, Cirrhosis, Liver
- Trial name
- NCT06537466
- Testing
- Mediterranean diet, Very Low Ketogenic Diet
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Palermo
Cancer, Hepatocellular
To Quantify the Impact of Addition of the GAAD Score to Imaging in Patients with Chronic Liver Disease Eligible for HCC Surveillance.
The goal of this prospective observational study is to test the impact of addition of the GAAD score to imaging in patients with chronic liver disease eligible for HCC surveillance.
- Trial name
- ADRENALIN (NCT06601231)
- Testing
- GAAD score
- Where
- Netherlands
- Volunteers
- 1,000 people
- Sponsor
- Erasmus Medical Center
Compensated Advanced Chronic Liver Disease
Impact of Metabolic Disorders on cACLD Outcomes
This multicenter, prospective, cohort study is designed to investigate how metabolic disorders (such as obesity, diabetes, and high cholesterol) influence the progression of liver disease in patients with compensated advanced…
- Trial name
- NCT07534046
- Testing
- Observational Study
- Volunteers
- 4,307 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
In this study, we aim to identify gut microbiomes specific to patients with chronic refractory liver disease and to conduct a gut-liver axis study on the pathogenesis and disease progression.
- Conditions
- Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Non-Alcoholic Fatty Liver Disease, Liver Abscess
- Trial name
- LGAS (NCT06519162)
- Where
- South Korea
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Chungnam National University Hospital
Autoimmune Liver Disease, Liver Transplant Disorder
A Study of SIPLIZUMAB in AILD and LT Patients
There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including…
- Conditions
- Autoimmune Liver Disease, Liver Transplant Disorder, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
- Trial name
- SET-SAIL (NCT06455280)
- Testing
- Siplizumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Elizabeth C. Verna
Autoimmune Hepatitis, Autoimmune Liver Disease
PredIcting sterOid depeNdEnt livEr injuRy With Polyreactive Immunoglobulin G
The investigators identified polyreactive immunoglobulin G (pIgG) in adults (published in Hepatology: https://doi.org/10.1002/hep.32134) and children (in preparation).
- Trial name
- PIONEER (NCT05810480)
- Testing
- polyreactive immunoglobulin G
- Where
- 6 sites in Germany
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Hannover Medical School
Chronic Liver Disease (CLD), Fibrosis of Liver
Assessing Signatures for Fibrosis Detection in Chronic Liver Disease: A Step Beyond Conventional Biomarkers
Morbidity and mortality of CLD is driven by the extent of liver fibrosis, characterized by scar formation and disruption of the normal liver architecture. HSCs play a central role in liver fibrosis development.
- Trial name
- NCT07359742
- Testing
- Blood draw for biomarkers
- Where
- Belgium
- Volunteers
- 110 people
- Sponsor
- Universitair Ziekenhuis Brussel
Fascioliasis
One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis
Randomized clinical trial comparing the efficacy and safety of oxfendazole at 20 mg/kg per dose in one and two dose regimens with a two-dose regimen of triclabendazole at 10 mg/kg in an endemic region of the highlands of Peru.
- Trial name
- NCT06367361
- Testing
- Oxfendazole, Triclabendazole
- Volunteers
- 336 people
- Sponsor
- Universidad Peruana Cayetano Heredia
Obesity, Morbid, NASH - Nonalcoholic Steatohepatitis
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
This study is being done to better understand the relationship between inflammation in adipose tissue (AT), abnormal deposition of fat around the liver and how this affects its appearance and function and ultimately insulin…
- Conditions
- Obesity, Morbid, NASH - Nonalcoholic Steatohepatitis, Chronic Inflammation
- Trial name
- NCT04232566
- Testing
- Bariatric surgery
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Hepatocellular Carcinoma, Liver Cirrhosis
Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC)
This prospective multicenter observational study evaluates the performance of a structured hepatocellular carcinoma (HCC) surveillance program in patients at increased risk of developing liver cancer.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Chronic Hepatitis B, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- Screening HCC (NCT07764835)
- Volunteers
- 300 people
- Sponsor
- D'Or Institute for Research and Education
Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency
Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)
This is a multicenter, parallel-group, double-blind, randomized phase 4 study designed to identify the optimal dose of CE1226 (2 active doses) to slow disease progression as assessed by reduced rates of annual lung density…
- Conditions
- Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency, Emphysema
- Trial name
- NCT07326592
- Testing
- CE1226
- Where
- 2 sites in Denmark
- Volunteers
- 270 people
- Sponsor
- CSL Behring
Hepatitis B, Acute-On-Chronic Liver Failure
Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF
This study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of HBV-related acute-on-chronic liver failure.
- Trial name
- HBV (NCT03920618)
- Testing
- Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Chronic Liver Disease, Cirrhosis
An Observational Study of Patients With Chronic Liver Disease
TARGET-Liver Disease (TARGET-LD) is an observational research study to conduct a comprehensive review of outcomes for patients with chronic liver disease (CLD).
- Trial name
- NCT05744713
- Testing
- Observational
- Where
- 10 sites in United States
- Volunteers
- 500,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Morbid Obesity, Type2diabetes
Comorbidities Resolution After MGB Surgery and Change in Body Composition
This observational study aims to learn about the correlation between the improving comorbidities associated with obesity after MGB (Mini-Gastric Bypass) surgery and changes in body composition in morbidly obese patients.
- Conditions
- Morbid Obesity, Type2diabetes, Sleep Apnea, Hypothyroidism
- Trial name
- MOGAMBO (NCT06015620)
- Testing
- Mini gastric bypass surgery
- Where
- India
- Volunteers
- 35 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Hepatitis B Virus Infection, Children
Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B
This study aims to evaluate the efficacy and safety of entecavir monotherapy versus sequential entecavir plus pegylated interferon α-2b in achieving functional cure in immune-tolerant, HBeAg-positive children aged 3-6 years with…
- Conditions
- Hepatitis B Virus Infection, Children, Chronic Hepatitis B
- Trial name
- NCT07345624
- Testing
- Entecavir, Entecavir + Pegylated interferon α-2b
- Volunteers
- 80 people
- Sponsor
- Qing-Lei Zeng
Acute Liver Failure, Acute on Chronic Liver Failure (ACLF)
Continuous Renal Replacement Therapy Intensity in Hyperammonemia
Acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) are life-threatening conditions often associated with hyperammonemia, hepatic encephalopathy, and multi-organ dysfunction.
- Conditions
- Acute Liver Failure, Acute on Chronic Liver Failure (ACLF), Acute Kidney Injury, Ammonia Metabolism
- Trial name
- CRITICAL (NCT06987604)
- Testing
- High-dose continuous renal replacement therapy, Conventional-dose continuous renal replacement therapy
- Where
- Brazil
- Volunteers
- 152 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Chronic Liver Disease
In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop
Control group : LAENNEC subcutaneous injection (4 ml) Experimental group : LAENNEC intravenous injection (10 ml)
- Trial name
- NCT06493799
- Testing
- LAENNEC (Human Placenta Hydrolysate) IV, LAENNEC (Human Placenta Hydrolysate) SC
- Where
- South Korea
- Volunteers
- 226 people
- Sponsor
- Green Cross Wellbeing
HEPATITIS B CHRONIC, Cirrhosis, Liver
Effect of Babao Dan Capsule Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis
This study aims to establish a prospective, multicenter, randomized, double-blind, placebo-controlled parallel-group clinical trial cohort.
- Conditions
- HEPATITIS B CHRONIC, Cirrhosis, Liver, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07544121
- Testing
- Babao Dan Capsule, Babao Dan Capsule simulant
- Volunteers
- 1,034 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatitis B, Chronic
Real-world Study Optimizing Nucleotide-analogues
The goal of this multicenter, observational, prospective study is to observe and compare different anti-viral treatment strategies in a real-world cohort of patients with CHB managed in routine clinical settings in China.
- Trial name
- NCT05937178
- Testing
- ETV/TAF/TDF/TMF/IFN, ETV/TAF/TDF/TMF
- Where
- 44 sites in China
- Volunteers
- 20,000 people
- Sponsor
- Huashan Hospital
Portal Hypertension
Non-Invasive Portal and Hepatic Vein Pressure Estimation
Background Portal hypertension (PH) is a spectrum of complications of end-stage liver disease (ESLD) and cirrhosis, with severe manifestations including ascites and gastroesophageal varices.
- Trial name
- NONEEDLES (NCT06210178)
- Testing
- Magnetic Resonance Imaging
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Leiden University Medical Center